O

Orchestra Biomed Holdings Inc
NASDAQ:OBIO

Watchlist Manager
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Watchlist
Price: 4.14 USD -1.66% Market Closed
Market Cap: 233.7m USD

Wall Street
Price Targets

OBIO Price Targets Summary
Orchestra Biomed Holdings Inc

Wall Street analysts forecast OBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OBIO is 13.84 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

Lowest
Price Target
10.1 USD
144% Upside
Average
Price Target
13.84 USD
234% Upside
Highest
Price Target
21 USD
407% Upside
Orchestra Biomed Holdings Inc Competitors:
Price Targets
NRXS
Neuraxis Inc
33% Upside
SMLR
Semler Scientific Inc
340% Upside
ATRC
AtriCure Inc
33% Upside
MDT
Medtronic PLC
16% Upside
HYPR
Hyperfine Inc
86% Upside
099190
I Sens Inc
60% Upside
SOON
Sonova Holding AG
9% Upside
ONWD
ONWARD Medical NV
137% Upside

Revenue
Forecast

Revenue Estimate
Orchestra Biomed Holdings Inc

The compound annual growth rate of Orchestra Biomed Holdings Inc's revenue for the next 4 years is 72%.

N/A
Past Growth
72%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Orchestra Biomed Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Orchestra Biomed Holdings Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is OBIO's stock price target?
Price Target
13.84 USD

According to Wall Street analysts, the average 1-year price target for OBIO is 13.84 USD with a low forecast of 10.1 USD and a high forecast of 21 USD.

What is Orchestra Biomed Holdings Inc's Revenue forecast?
Projected CAGR
72%

The compound annual growth rate of Orchestra Biomed Holdings Inc's revenue for the next 4 years is 72%.

Back to Top